An interesting comparison:NXS v ANO another ASX listed Biotech...

An interesting comparison:

NXS v ANO another ASX listed Biotech company (You can guess if you like, but the point is more on valuation and market mispricing)

Market Cap:
NXS - $110m
ANO - $90m

Sales:
NXS - 2023 $33.5m, forecast 2024 $60m
ANO - 2023 NIL, forecast 2024 NIL

FDA Approved Products:
NXS - Multiple ((with 56 patents)
ANO - NIL

Forecast Breakeven by:
NXS - 2024
ANO - They might suggest its in the next 5 years, but they don't even have an FDA approved product.

I think that the NXS current share price is insane.

Considering the above and all Montytheman's points, I am really bullish.

DYOR though, I bought too much of my current holding way too early. I didn't foresee the difficulty they would have with partners and with cost and pace of customer acquisition. But I firmly believe that they now have significant tailwinds. Last piece of the puzzle in the near term is achieving quarterly progress towards their 2024 goals of being cashflow positive and achieving US$ sales of over $36m.